Ray Dalio's IDXX Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 10,314 shares of IDEXX Laboratories, Inc. (IDXX) worth $5.8 M, representing 0.03% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Ray Dalio has maintained a long-term strategic position in IDXX, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2022, adding 35,770 shares. Largest reduction occurred in Q4 2023, reducing 57,969 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's IDEXX Laboratories (IDXX) Holding Value Over Time
Track share changes against reported price movement
Quarterly IDEXX Laboratories (IDXX) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +4,156 | Add 67.49% | 10,314 | $561.89 |
| Q4 2025 | -1,246 | Reduce 16.83% | 6,158 | $676.53 |
| Q3 2025 | +4,779 | Add 182.06% | 7,404 | $638.89 |
| Q2 2025 | -809 | Reduce 23.56% | 2,625 | $536.34 |
| Q1 2025 | -5,427 | Reduce 61.25% | 3,434 | $419.95 |
| Q4 2024 | -3,888 | Reduce 30.50% | 8,861 | $413.44 |
| Q3 2024 | -19,677 | Reduce 60.68% | 12,749 | $505.22 |
| Q2 2024 | -2,099 | Reduce 6.08% | 32,426 | $487.20 |
| Q1 2024 | -24,337 | Reduce 41.35% | 34,525 | $539.93 |
| Q4 2023 | -57,969 | Reduce 49.62% | 58,862 | $555.05 |
| Q3 2023 | +9,096 | Add 8.44% | 116,831 | $437.27 |
| Q2 2023 | +4,363 | Add 4.22% | 107,735 | $502.23 |
| Q1 2023 | -17,392 | Reduce 14.40% | 103,372 | $500.08 |
| Q4 2022 | -23,409 | Reduce 16.24% | 120,764 | $407.96 |
| Q3 2022 | +6,972 | Add 5.08% | 144,173 | $325.80 |
| Q2 2022 | -2,240 | Reduce 1.61% | 137,201 | $350.73 |
| Q1 2022 | +35,770 | Add 34.50% | 139,441 | $547.06 |
| Q4 2021 | +15,166 | Add 17.14% | 103,671 | $658.46 |
| Q3 2021 | +17,821 | Add 25.21% | 88,505 | $621.90 |
| Q2 2021 | +28,974 | Add 69.47% | 70,684 | $631.54 |
| Q1 2021 | -1,027 | Reduce 2.40% | 41,710 | $489.31 |
| Q4 2020 | +21,984 | Add 105.93% | 42,737 | $499.87 |
| Q3 2020 | +20,753 | New Buy | 20,753 | $393.10 |
| Q2 2020 | -2,702 | Sold Out | 0 | $0.00 |
| Q1 2020 | +2,702 | New Buy | 2,702 | $242.41 |
| Q4 2019 | -3,646 | Sold Out | 0 | $0.00 |
| Q3 2019 | +3,646 | New Buy | 3,646 | $271.80 |
| Q1 2019 | -8,348 | Sold Out | 0 | $0.00 |
| Q4 2018 | +8,348 | New Buy | 8,348 | $186.03 |
| Q3 2018 | -2,501 | Sold Out | 0 | $0.00 |
| Q2 2018 | -2,994 | Reduce 54.49% | 2,501 | $217.91 |
| Q1 2018 | +5,495 | New Buy | 5,495 | $191.45 |
| Q4 2017 | -1,743 | Sold Out | 0 | $0.00 |
| Q3 2017 | +1,743 | New Buy | 1,743 | $155.48 |
| Q4 2015 | -7,826 | Sold Out | 0 | $0.00 |
| Q3 2015 | +3,600 | Add 85.19% | 7,826 | $74.24 |
| Q2 2015 | +4,226 | New Buy | 4,226 | $64.13 |
| Q4 2014 | -14,226 | Sold Out | 0 | $0.00 |
| Q3 2014 | +14,226 | New Buy | 14,226 | $58.91 |
| Q2 2014 | -4,602 | Sold Out | 0 | $0.00 |
| Q1 2014 | +4,602 | New Buy | 4,602 | $60.63 |
Ray Dalio's IDEXX Laboratories Investment FAQs
Ray Dalio first purchased IDEXX Laboratories, Inc. (IDXX) in Q1 2014, acquiring 4,602 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held IDEXX Laboratories, Inc. (IDXX) for 41 quarters since Q1 2014.
Ray Dalio's largest addition to IDEXX Laboratories, Inc. (IDXX) was in Q1 2022, adding 139,441 shares worth $76.28 M.
According to the latest 13F filing for Q1 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 10,314 shares of IDEXX Laboratories, Inc. (IDXX), valued at approximately $5.8 M.
As of the Q1 2026 filing, IDEXX Laboratories, Inc. (IDXX) represents approximately 0.03% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in IDEXX Laboratories, Inc. (IDXX) was 144,173 shares, as reported at the end of Q3 2022.